Post-traumatic stress disorder (PTSD) can cause an array of adverse mental health effects, but physical side effects are also common.

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...

Regenxbio Inc., a leading clinical─stage biotechnology company, announced positive results from the phase I/II/III CAMPSIITE trial of RGX─121 for...

More hospitals and clinics now offer patients ketamine therapy for severe depression, post-traumatic stress disorder and other mental health...

Relief Therapeutics Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare...

HOUSTON, Sept. 9, 2024. Moleculin Biotech, Inc., ("Moleculin" or the "Company), a Phase 3 clinical-stage pharmaceutical company with a broad portfolio...

From Aug. 11 to 19, Sgt. Rob Nederlof pedalled the highways between Edmonton and Regina on his bike. This was the fourth year for the ride, which...